A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer.

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 03 May 2018

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Atezolizumab (Primary) ; Varlilumab (Primary)
Indications Bladder cancer; Breast cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
Focus Adverse reactions
Sponsors Celldex Therapeutics Inc

15 Mar 2017 Status changed from recruiting to discontinued.
14 Mar 2017 According to a Celldex Therapeutics media release, company has decided not to advance the varlilumab/Tecentriq combination studies in renal cell carcinoma to Phase 2, due to cost-containment.
08 Aug 2016 According to a Celldex Therapeutics media release, enrollment has been completed in the phase I dose-escalation portion and the company anticipates to initiate the phase II portion of the study in renal cell carcinoma in the third quarter of 2016.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com